Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of beclometasone (SGX203) in paediatric patients with Crohn's disease

Next Previous
Trial Profile

Phase III trial of beclometasone (SGX203) in paediatric patients with Crohn's disease

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Beclometasone (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 29 Jul 2019 According to a Soligenix media release, the conduct of this trial is pending partnership and/or additional funding.
  • 26 Jan 2016 According to a Soligenix media release, this trial is expected to be initiated during the first half of 2016.
  • 14 Apr 2015 Primary results are expected to be available in the first half of 2017, according to a Soligenix media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top